Search hospitals > Tennessee > Collierville
Baptist Memorial Hospital and Cancer Center-Collierville
Claim this profileCollierville, Tennessee 38017
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
93 reported clinical trials
21 medical researchers
Summary
Baptist Memorial Hospital and Cancer Center-Collierville is a medical facility located in Collierville, Tennessee. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Baptist Memorial Hospital and Cancer Center-Collierville is involved with conducting 93 clinical trials across 218 conditions. There are 21 research doctors associated with this hospital, such as Philip E. Lammers, Raymond U. Osarogiagbon, Stephen W. Behrman, and Donald S. Gravenor.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Philip E. LammersBaptist Memorial Hospital and Cancer Center-Memphis4 years of reported clinical research
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
35 drugs studied
Raymond U. OsarogiagbonBaptist Memorial Hospital and Cancer Center-Memphis5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
27 drugs studied
Stephen W. BehrmanBaptist Memorial Hospital and Cancer Center-Memphis5 years of reported clinical research
Studies Pancreatic Cancer
Studies Cancer
7 reported clinical trials
20 drugs studied
Donald S. GravenorBaptist Memorial Hospital and Cancer Center-Oxford7 years of reported clinical research
Studies Cancer
Studies Pancreatic Cancer
6 reported clinical trials
34 drugs studied
Clinical Trials running at Baptist Memorial Hospital and Cancer Center-Collierville
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Pancreatic Cancer
Pancreatic Carcinoma
Gallbladder Cancer
Squamous Cell Carcinoma
Pancreatic Neuroendocrine Tumors
Colorectal Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Baptist Memorial Hospital and Cancer Center-Collierville?
Baptist Memorial Hospital and Cancer Center-Collierville is a medical facility located in Collierville, Tennessee. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Baptist Memorial Hospital and Cancer Center-Collierville is involved with conducting 93 clinical trials across 218 conditions. There are 21 research doctors associated with this hospital, such as Philip E. Lammers, Raymond U. Osarogiagbon, Stephen W. Behrman, and Donald S. Gravenor.